2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10: 1027-1035. PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXAdjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Sutton T, Billingsley K, Johnson A, Corless C, Blanke C, Heinrich M, Mayo S. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? Journal Of Surgical Oncology 2024, 130: 40-46. PMID: 38924626, DOI: 10.1002/jso.27654.Peer-Reviewed Original ResearchHigh-risk gastrointestinal stromal tumorsRecurrence-free survivalGastrointestinal stromal tumorsResected gastrointestinal stromal tumorsAdjuvant imatinibOverall survivalStromal tumorsAdjuvant therapyDuration of adjuvant imatinibBenefit of adjuvant therapyMonths of postsurgical follow-upMultivariate Cox proportional hazards modelPostsurgical follow-upKaplan-Meier analysisCox proportional hazards modelsProportional hazards modelRadiographic recurrenceImatinib resistanceReviewed patientsFollow-upImatinibOncological treatmentCytocidal effectCancer CenterPatientsReasonable expansion of surgical candidates for HCC treatment
Butensky S, Billingsley K, Khan S. Reasonable expansion of surgical candidates for HCC treatment. Clinical Liver Disease 2024, 23: e0153. PMID: 38720794, PMCID: PMC11078523, DOI: 10.1097/cld.0000000000000153.Peer-Reviewed Original ResearchMo1492 EFFECTS OF THE HEALTH INSURANCE MARKETPLACE ON GASTROINTESTINAL CANCER SURGERY OUTCOMES
Butensky S, Kerekes D, Bakkila B, Kurbatov V, Kunstman J, Billingsley K, Khan S. Mo1492 EFFECTS OF THE HEALTH INSURANCE MARKETPLACE ON GASTROINTESTINAL CANCER SURGERY OUTCOMES. Gastroenterology 2024, 166: s-1891. DOI: 10.1016/s0016-5085(24)04833-9.Peer-Reviewed Original Research
2023
Impact of COVID-19 on the gastrointestinal surgical oncology patient population
Bakkila B, Marks V, Kerekes D, Kunstman J, Salem R, Billingsley K, Ahuja N, Laurans M, Olino K, Khan S. Impact of COVID-19 on the gastrointestinal surgical oncology patient population. Heliyon 2023, 9: e18459. PMID: 37534012, PMCID: PMC10391949, DOI: 10.1016/j.heliyon.2023.e18459.Peer-Reviewed Original ResearchGI cancer surgeryPreoperative chemotherapyCancer surgerySurgical careCOVID-19 pandemicCOVID-19Tertiary referral centerOncology patient populationFirst COVID-19 waveGI cancer casesCOVID-19 burdenHigh COVID-19 burdenEmergency surgeryReferral centerCOVID-19 waveOncology visitsGastrointestinal cancerGI cancersPatient populationStudy criteriaCancer careTreatment characteristicsCancer casesCase volumePatientsPhase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodesHepatopancreatobiliary malignancies: time to treatment matters
Kerekes D, Frey A, Bakkila B, Johnson C, Becher R, Billingsley K, Khan S. Hepatopancreatobiliary malignancies: time to treatment matters. Journal Of Gastrointestinal Oncology 2023, 0: 0-0. PMID: 37201090, PMCID: PMC10186552, DOI: 10.21037/jgo-22-1067.Peer-Reviewed Original ResearchTreatment initiationStage IHPB cancersStage I pancreatic cancerExtrahepatic bile duct cancerKaplan-Meier survival analysisHPB cancer patientsNational Cancer DatabaseRetrospective cohort studyBile duct cancerMedian treatment initiationHepatopancreatobiliary cancersMedian survivalCohort studyDuct cancerOverall survivalHispanic patientsEHBD cancerOncologic careBile ductCox regressionBlack raceCancer patientsDefinitive carePancreatic cancerOutcomes on an inpatient oncology service after the introduction of hospitalist comanagement
Morris J, Rothberg BE, Prsic E, Parker N, Weber U, Gombos E, Kottarathara M, Billingsley K, Adelson K. Outcomes on an inpatient oncology service after the introduction of hospitalist comanagement. Journal Of Hospital Medicine 2023, 18: 391-397. PMID: 36891947, DOI: 10.1002/jhm.13071.Peer-Reviewed Original ResearchConceptsLength of stayInpatient oncology serviceSmilow Cancer HospitalSeverity of illnessOncology servicesOncologists' experiencesReadmission ratesEarly dischargeHospitalist comanagementAverage LOSTime of dischargeMean discharge timeEarly discharge ratesImpact of hospitalistsRace/ethnicityDischarge dispositionMultiple admissionsCancer HospitalMAIN OUTCOMEStudy durationPatient volumeCancer typesStudy periodHospitalistsOutcomes
2022
Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis
Sutton T, Wong L, Walker B, Dewey E, Eil R, Lopez C, Kardosh A, Chen E, Rocha F, Billingsley K, Mayo S. Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis. Surgery 2022, 173: 1314-1321. PMID: 36435651, DOI: 10.1016/j.surg.2022.10.019.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesPost-recurrence overall survivalRepeat hepatic resectionRecurrent colorectal liver metastasesHepatic resectionLiver metastasesSystemic treatmentOverall survivalIntrahepatic recurrenceOncologic outcomesSystemic therapyMedian post-recurrence overall survivalRetrospective single-institution cohort studySingle-institution cohort studyCurative-intent hepatectomyImproved oncologic outcomesPerioperative systemic therapyRelevant clinicopathologic variablesSignificant clinicopathologic differencesPropensity-matched analysisRole of resectionCox proportional hazardsLiver recurrencePerioperative chemotherapyCohort studyHepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone
Sutton T, Walker B, Billingsley K, Sheppard B, Corless C, Heinrich M, Mayo S. Hepatic Metastases in Gastrointestinal Stromal Tumors: Oncologic Outcomes with Curative-Intent Hepatectomy, Resection of Treatment-Resistant Disease, and Tyrosine Kinase Inhibitor Therapy Alone. Hepato Pancreato Biliary 2022, 24: s90-s91. DOI: 10.1016/j.hpb.2022.05.170.Peer-Reviewed Original Research
2021
ASO Visual Abstract: The Disease-Free Interval is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor
Sutton T, Walker B, Billingsley K, Sheppard B, Corless C, Heinrich M, Mayo S. ASO Visual Abstract: The Disease-Free Interval is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor. Annals Of Surgical Oncology 2021, 28: 426-427. DOI: 10.1245/s10434-021-10107-w.Peer-Reviewed Original Research
2020
Neoadjuvant Chemotherapy or Chemoradiotherapy Does Not Increase Early and Late Post-operative Complication Rates Following Definitive Resection for Pancreatic Ductal Adenocarcinoma
Deig C, Stratton A, Trone K, Beneville B, Liu A, Kanwar A, Bassale S, Chen Y, Grossblatt-Wait A, Attia F, Sheppard B, Keith D, Chen E, Lopez C, Billingsley K, Gilbert E, Nabavizadeh N, Thomas C, Grossberg A. Neoadjuvant Chemotherapy or Chemoradiotherapy Does Not Increase Early and Late Post-operative Complication Rates Following Definitive Resection for Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e606-e607. DOI: 10.1016/j.ijrobp.2020.07.1845.Peer-Reviewed Original ResearchBorderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients
Deig C, Trone K, Beneville B, Stratton A, Liu A, Kanwar A, Grossblatt-Wait A, Sheppard B, Attia F, Bassale S, Chen Y, Keith D, Chen E, Lopez C, Gilbert E, Billingsley K, Nabavizadeh N, Thomas C, Grossberg A. Borderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e581-e582. DOI: 10.1016/j.ijrobp.2020.07.1786.Peer-Reviewed Original ResearchPandemic Recovery Using a COVID-Minimal Cancer Surgery Pathway
Boffa DJ, Judson BL, Billingsley KG, Galetta D, Fontanez P, Odermatt C, Lindner K, Mitchell MR, Henderson CM, Carafeno T, Pinto J, Wagner J, Ancuta M, Beley P, Turner AL, Banack T, Laurans MS, Johnson DC, Yoo P, Morton JM, Zurich H, Davis K, Ahuja N. Pandemic Recovery Using a COVID-Minimal Cancer Surgery Pathway. The Annals Of Thoracic Surgery 2020, 110: 718-724. PMID: 32417195, PMCID: PMC7227551, DOI: 10.1016/j.athoracsur.2020.05.003.Peer-Reviewed Original ResearchConceptsSurgery pathwayHospital-acquired COVID-19 infectionLarge academic medical centerCOVID-19 patientsCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 infectionPatient care pathwayAcademic medical centerDisease 2019 pandemicHealth care deliveryOnly surgerySurgery populationElective surgeryPatient survivalRisk of exposureProtection of patientsCare pathwayNosocomial infectionsMedical CenterCare deliverySurgical activityHospitalPatientsSurgeryMost hospitalsYttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q, Schenning RC, Jahangiri Y, Tomozawa Y, Kolbeck KJ, Kaufman JA, Al-Hakim R, Naugler WE, Nabavizadeh N, Kardosh A, Billingsley KG, Mayo SC, Orloff SL, Enestvedt KK, Maynard E, Ahn J, Lhewa D, Farsad K. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child–Pugh A Versus B7 Patients: Are the Outcomes Equivalent? CardioVascular And Interventional Radiology 2020, 43: 721-731. PMID: 32140840, DOI: 10.1007/s00270-020-02434-4.Peer-Reviewed Original ResearchConceptsC hepatocellular carcinomaChild-Pugh AAdvanced hepatocellular carcinomaOverall survivalHepatocellular carcinomaBCLC stage C hepatocellular carcinomaEastern Cooperative Oncology Group scoreBCLC-C hepatocellular carcinomasMultivariable Cox regression analysisChild-Pugh scoreMedian overall survivalChild-Pugh classKaplan-Meier methodCox regression analysisYttrium-90 RadioembolizationLog-rank testCautious patient selectionSignificant independent predictorsChild-PughHCV infectionResultsMean ageY90 radioembolizationAdditional malignanciesConsecutive patientsIndependent predictorsEffect of Time to Surgery of Colorectal Liver Metastases on Survival
Chen EY, Mayo SC, Sutton T, Kearney MR, Kardosh A, Vaccaro GM, Billingsley KG, Lopez CD. Effect of Time to Surgery of Colorectal Liver Metastases on Survival. Journal Of Gastrointestinal Cancer 2020, 52: 169-176. PMID: 32086781, PMCID: PMC7900034, DOI: 10.1007/s12029-020-00372-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantColorectal NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRetrospective StudiesTime FactorsTime-to-TreatmentYoung AdultConceptsColorectal liver metastasesLong-term OSPostoperative overall survivalOverall survivalLonger TTSLiver metastasesWorse survivalDiagnosis of CLMLong-term survivorsResultsTwo hundred eightyRisk of recurrenceComprehensive cancer centerHigh disease burdenSpecific primary tumorsShorter TTSPerioperative chemotherapyPostoperative chemotherapyPerioperative treatmentResection marginsCancer CenterMetastasis characteristicsInstitutional databasePrimary tumorDisease burdenSimilar survivalPerioperative complication rates following neoadjuvant therapy in pancreatic adenocarcinoma.
Deig C, Beneville B, Liu A, Kanwar A, Grossblatt-Wait A, Sheppard B, Gilbert E, Lopez C, Billingsley K, Nabavizadeh N, Thomas C, Grossberg A. Perioperative complication rates following neoadjuvant therapy in pancreatic adenocarcinoma. Journal Of Clinical Oncology 2020, 38: 688-688. DOI: 10.1200/jco.2020.38.4_suppl.688.Peer-Reviewed Original ResearchPerioperative complication rateNeoadjuvant therapyComplication ratePancreatic adenocarcinomaNeo-CRTUpfront resectionUpfront surgeryHospital lengthExact testComparable perioperative complication ratesSignificant differencesAcademic tertiary referral centerInstitutional cancer registryMedian hospital lengthNeoadjuvant radiation therapyPatients Undergoing ResectionTotal neoadjuvant therapyPost-operative mortalityTertiary referral centerResectable pancreatic adenocarcinomaAdditional surgical riskFisher's exact testT-testStudent's t-testUndergoing resectionPhase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Chen E, Tormoen G, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G. Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma. Journal Of Clinical Oncology 2020, 38: 697-697. DOI: 10.1200/jco.2020.38.4_suppl.697.Peer-Reviewed Original ResearchGemcitabine/nab-paclitaxelPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaPre-operative therapyPre-operative treatmentNab-paclitaxelPancreatic resectionDuctal adenocarcinomaBorderline resectable pancreatic ductal adenocarcinomaSingle-arm phase II trialNab-paclitaxel chemotherapyPositive clinical nodesPhase II studyR0 resection ratePhase II trialNegative surgical marginsRelapse-free survivalMicro-metastatic diseaseIntensity-modulated radiation therapyGemcitabine 1000II trialPrimary endpointResection rateSecondary endpointsII studyHepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program
Walker B, Billingsley K, Sutton T, Zarour L, Kolbeck K, Korngold E, Chen E, Kardosh A, Herzig D, Tsikitis V, Nabavizadeh N, Dewey E, Lopez C, Mayo S. Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program. Hepato Pancreato Biliary 2020, 22: s123-s124. DOI: 10.1016/j.hpb.2020.04.630.Peer-Reviewed Original ResearchDetection Of Tumor Multifocality In Resectable Intrahepatic Cholangiocarcinoma: Defining The Optimal Pre-Operative Imaging Modality
Sutton T, Billingsley K, Walker B, Fung A, Maynard E, Enestvedt K, Dewey E, Brinkerhoff B, Lopez C, Orloff S, Mayo S. Detection Of Tumor Multifocality In Resectable Intrahepatic Cholangiocarcinoma: Defining The Optimal Pre-Operative Imaging Modality. Hepato Pancreato Biliary 2020, 22: s45-s46. DOI: 10.1016/j.hpb.2020.04.861.Peer-Reviewed Original Research